Life Sciences & Biotechnology

CSIR-CDRI has identified a novel small molecule abbreviated as 99/373 which is aryl napthyl derivative. It specifically inhibits differentiation of bone marrow cells to osteoclasts and disrupts actin ring formation, a surrogate for bone resorption activity by the osteoclasts. This molecule in its category has been found to be more effective than Raloxifene available in the market. This antiresorptive molecule has potential application in reducing the risk of post menopausal osteoporosis.